What Is the WiSeR Model in Wound Care? Prior Authorization Requirements Explained
The WiSeR model explained — CMS's Wound Care, Skin Substitutes, and Evaluation Registry pilot program, how it affects prior authorization, and what wound care practices need to know.
Damon Ebanks
Medipyxis
What Is the WiSeR Model?
WiSeR stands for Wound Care, Skin Substitutes, and Evaluation Registry. It is a CMS pilot program that creates a structured registry and prior authorization framework for skin substitute applications under Medicare. Participating providers must submit clinical data about each CTP application -- wound type, size, duration, prior treatments, and the specific product proposed -- into a centralized registry before and after treatment.
WiSeR is not a coverage policy. It layers on top of existing Medicare coverage rules. Practices in participating jurisdictions must satisfy WiSeR submission requirements in addition to meeting standard LCD documentation criteria and skin substitute billing requirements.
Why Did CMS Create WiSeR?
Two problems drove the program.
Spending growth without outcome data. Medicare spending on skin substitutes grew substantially over the past decade, but CMS had limited visibility into whether those products were producing better wound healing outcomes than standard wound care. WiSeR collects the data CMS lacked -- wound closure rates, time to healing, recurrence, and adverse events tied to specific products.
Appropriateness concerns. CMS observed wide variation in skin substitute utilization across providers and geographies. WiSeR gives CMS a mechanism to track utilization at the provider level and flag outlier prescribing for review.
Which MACs and States Participate?
WiSeR does not apply nationwide. The program launched as a regional pilot tied to specific MAC jurisdictions. Participation is determined by the MAC that processes your claims, based on the geographic location where the service is rendered -- not where your practice is headquartered.
As of 2026, participating MACs include Palmetto GBA and Novitas Solutions, covering jurisdictions across the Southeast, Mid-Atlantic, and parts of the Midwest. CMS has indicated that additional MACs may be added in future rulemaking cycles.
If you are unsure whether your MAC participates: check your MAC's provider communications portal. WiSeR participation is communicated through MAC provider bulletins.
Mobile wound care providers take note: if you render services in a WiSeR-participating jurisdiction but are based elsewhere, WiSeR requirements still apply to those claims because jurisdiction follows the place of service.
How Does WiSeR Affect Prior Authorization?
WiSeR introduces a structured prior authorization-like process for skin substitute applications in participating jurisdictions. The mechanics differ from traditional PA in important ways.
Registry submission before treatment. Before applying a skin substitute, the provider must submit clinical data to the WiSeR registry -- wound type, size, duration, location, prior treatments attempted, and the specific product proposed.
Prospective review, not approval. WiSeR submissions undergo review, but the process is not a binary approve/deny gate. CMS uses registry data for utilization tracking and post-payment audit targeting. A completed submission does not guarantee payment.
Post-treatment outcome reporting. Practices must report wound status at defined intervals following application -- wound measurements, healing trajectory, and whether additional applications were performed. Traditional PA does not include this outcome-tracking component.
The practical impact: WiSeR adds a data submission step before and after every skin substitute application, on top of existing LCD documentation and standard claims submission.
What Documentation Changes Do Practices Need to Make?
WiSeR does not replace existing documentation requirements. It adds structured data elements that most EMR templates were not built to capture:
- Wound assessment -- wound type by etiology, dimensions in cm, anatomical site, wound duration, and wound bed characteristics
- Prior treatment history -- conservative treatments attempted, duration, and documented failure to respond
- Product selection rationale -- the specific CTP product and clinical reasoning for selecting it
- Outcome measurements -- post-application wound status at defined follow-up intervals, including size reduction percentage
The key difference from LCD documentation: WiSeR requires structured data fields, not free-text narrative. A clinical note that satisfies an LCD auditor may not contain the structured data WiSeR requires. Practices need to audit their templates and build workflows where the WiSeR submission is completed before each application -- this is clinical data that only the treating provider can supply.
How Does WiSeR Relate to Existing LCDs?
WiSeR operates alongside LCDs, not in place of them.
LCDs define coverage criteria. Your MAC's LCD still determines whether a skin substitute application is covered. The wound must qualify under the LCD's clinical criteria -- wound type, chronicity, failed conservative therapy, frequency limits -- for the claim to be payable. LCDs have not been replaced by WiSeR.
WiSeR adds utilization tracking. Satisfying WiSeR submission requirements does not mean your claim meets LCD criteria, and meeting LCD criteria does not satisfy WiSeR. They are parallel obligations.
Where they overlap: both require wound measurements, etiology, conservative treatment history, and medical necessity. If your documentation already meets LCD requirements, you have most of the clinical data WiSeR needs. The gap is structured format and post-treatment outcome reporting, which LCDs do not require.
Frequently Asked Questions
Does WiSeR apply to all wound care services? No. WiSeR targets skin substitute and CTP applications specifically. Debridement, E/M visits, NPWT, and other wound care services are not part of the registry.
Does WiSeR replace prior authorization for Medicare Advantage plans? No. WiSeR is a Medicare FFS program. MA plans have their own PA requirements that are separate from WiSeR. A practice in a WiSeR jurisdiction treating an MA patient may need to satisfy both.
Does WiSeR affect which products I can use? WiSeR does not independently restrict the product list. However, registry outcome data may influence future coverage decisions -- products with poor outcomes could face restrictions in subsequent rulemaking.
Is WiSeR permanent? It launched as a pilot. CMS can expand it to additional jurisdictions, modify requirements, or make it permanent based on pilot data. Plan as though it will expand.